Sunshine Biopharma cuts Series B warrant exercise price to $1.2046 after at-the-market sales
Sunshine Biopharma said that recent sales of its common stock under its at-the-market offering triggered a reduction in the exercise price of its outstanding Series B Warrants to $1.2046. The price is subject to further adjustment under the warrant terms. The change lowers the price at which warrant holders can buy shares, which could increase potential dilution for existing shareholders.
Key points
- Series B Warrant exercise price reduced to $1.2046 per share
- Reduction tied to recent sales of common stock under the at-the-market offering
- Exercise price remains subject to further adjustment under the Series B Warrant terms
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.